MedPath

Correlation Between PTP1B Expression and Organ Failure During Sepsis

Not Applicable
Completed
Conditions
Sepsis
Interventions
Biological: PTP1B dosage
Registration Number
NCT02295514
Lead Sponsor
University Hospital, Rouen
Brief Summary

Despite major advances in the treatment and understanding of the pathophysiological mechanisms, mortality of severe sepsis remains high, ranging from 25 to 50%. With a prevalence \> 20% in intensive care units, it is now in a population increasingly aging with many co-morbidities, a real public health problem. Thus, changes in treatment to physiological axes could change the prognosis of these patients. Protein Tyrosine Phosphatase 1B (PTP1B) is involved in the negative regulation of many cellular pathways such as the response to insulin, leptin and certain growth factors and endothelial nitric oxide production. PTP1B appears to be particularly involved in the control of endothelial function and insulin secretion. Under these conditions, encouraging results have been obtained in a model of insulin resistance (obesity, diabetes) and as part of pro-angiogenic therapy by inhibition of PTP1B on models of heart failure. Recent advances have broadened the pathophysiological implications of PTP1B conferring a potential role in the regulation of inflammatory processes. In an experimental model of septic shock (Inserm 1096), the investigators demonstrated a significant improvement in survival and cardiovascular function in genetically deficient mice PTP1B (PTP1B - / -). Finally, PTP1B is involved in the downregulation of the signaling pathway of insulin via a feedback phenomenon. Septic shock induces many changes in carbohydrate metabolism. These changes result in hyperglycemia associated with insulin resistance, an independent risk factor of morbidity and mortality. Taken together, these data suggest that the expression of PTP1B could be useful in septic patients by modulating insulin resistance and thus the prognosis of these patients. This justifies the investigator clinical research project on the relationship between the expression of PTP1B levels, glycemic status and prognosis evaluated by the SOFA score in patients with septic shock with multiple organ failure.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Patients in ICU for septic shock
  • Person belonging to a social security system
  • Informed patient who signed consent
  • Contraceptive method in women of reproductive age
Exclusion Criteria
  • Pregnancy
  • Patient not able to take a decision because of an administrative or legal decision
  • Patient participating to an other interventional study
  • BMI > 30 kg/m2
  • Diabetes with specific treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PTP1B dosagePTP1B dosagePTP1B dosage during sepsis
Primary Outcome Measures
NameTimeMethod
Change from baseline in PTP1B level expressionDay 5

Change from baseline in PTP1B level expression by biological analysis

Number of patients with organ failureDay 5

Number of patients with organ failure

Secondary Outcome Measures
NameTimeMethod
Insulin resistance evaluationDay 1

Evaluation of insulin resistance by biological analysis

Blood glucose AnalysisDay 5

Analysis of the variability in Blood glucose

Number of death participants at at the end of the studyDay 28

Mortality at day 28

Number of death participants at at hospital discharge10 days (average)

Mortality at hospital discharge, average of 10 days after surgical intervention

Dose of insulin administered during the sepsisDay 5

cumulative dose of insulin administered in the first 5 days of hospitalization

Duration of mechanical ventilationDay 28

Duration of mechanical ventilation from admission to discharge

Number of death participants at ICU dischargeICU discharge, day 28

ICU mortality at day 28

Trial Locations

Locations (1)

Rouen University Hospital

🇫🇷

Rouen, France

© Copyright 2025. All Rights Reserved by MedPath